HALIFAX,
Sept. 26, 2013 /CNW/ - MedMira Inc.,
(MedMira) (TSXV: MIR), a developer of rapid diagnostic technology
and solutions, today announced the expansion of its organization
with the hiring of key team members and new offices in the US and
Switzerland as it makes its next
move to strengthen its sales and business development
programs. Joining MedMira are Kevin
Jones, Ph.D. as Senior Director, Global Sales &
Marketing and Markus Meile in the
role of Senior Director, International Markets.
Dr. Jones brings over 20 years of significant
industry experience to MedMira and has demonstrated successes in
sales and marketing in medical, diagnostics, and life sciences
sectors as well as product research, development and launch;
building technology support apparatus; and business strategy. Most
recently he worked with Avery Dennison Medical Solutions as Global
Segment Market Manager. Prior to that he worked with EDP
Biotech, Whatman Inc., and British BioCell InternationaI in various
international roles. At MedMira, Dr. Jones will lead global
sales and marketing programs, initially targeting the United States market with a focus on the
launch of new products in the Reveal and Multiplo ranges as well as
expanding Miriad, a research and development tool, into new market
areas.
"MedMira, with its patented rapid flow-through
technology that delivers almost instant results, is now ready to
move boldly into new markets," said Dr. Jones shortly after his
appointment. "The capital investment that was recently put in
place, along with the new Reveal and Multiplo products that will be
launched in the US and internationally beginning in 2014, will
enable MedMira to grow significantly over the next two years."
To achieve its commercial targets MedMira has
expanded its operations to include new offices in the United States, Switzerland, as well as a realigned sales and
marketing team at the Company's corporate headquarters in
Halifax, NS. Additionally,
Markus Meile, a MedMira board
member, has agreed to join the Company on a full-time basis.
He will lead MedMira's international business development
initiatives, cultivating and managing relationships with various
government agencies, aid organizations, and NGOs to ensure the
Company's rapid diagnostic solutions are a part of the efforts to
address global healthcare challenges such as HIV and Hepatitis.
"I am very pleased that Markus can join us in a
full-time role," said Dr. Jones. "He adds a wealth of experience in
international markets and brings connections in the key
organizations which will help us achieve our financial and
corporate goals."
About MedMira
MedMira is a leading developer and manufacturer
of flow-through rapid diagnostics. The Company's rapid tests
provide hospitals, labs, clinics and individuals with reliable,
nearly instant diagnosis for diseases such as HIV and hepatitis C.
MedMira tests are sold under the Reveal®, Multiplo™ and Miriad
brands in global markets. MedMira's rapid flow-through HIV test is
the only one in the world to achieve regulatory approvals in
Canada, the United States, China and the European Union. MedMira's
corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada and
the Company has sales and business development offices in
the United States and Switzerland. For more information visit
www.medmira.com.
This news release contains forward-looking
statements, which involve risk and uncertainties and reflect the
Company's current expectation regarding future events including
statements regarding possible approval and launch of new products,
future growth, and new business opportunities. Actual events
could materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from
time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE MEDMIRA INC.
